Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCardiaBCDA 25 6-1 Month Momentum % is -3.23% as of Aug. 06, 2026. GuruFocus rates BCDA with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,383 Biotechnology companies, BioCardia ranks better than 57.92% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-06), BioCardia's 6-1 Month Momentum % is -3.23%.
The industry rank for BioCardia's 6-1 Month Momentum % or its related term are showing as below:
BCDA's 6-1 Month Momentum % is ranked better than 57.92% of 1383
companies
in the Biotechnology industry
Industry Median: -10.85
vs BCDA: -3.23
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BioCardia 6-1 Month Momentum % Related Terms
BCDA vs SNTI, COCP, ZEOX: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, BioCardia's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCardia 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCardia's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BioCardia's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCardia (BCDA) has a 6-1 Month Momentum % of -3.23% as of Aug. 06, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on BioCardia and its competitors. According to the industry distribution chart, BioCardia ranks #582 out of 1383 companies in the Biotechnology industry, placing it in the top 42.1%.
Is BioCardia's 6-1 Month Momentum % too high?
BioCardia's current 6-1 Month Momentum % is -3.23%. Based on the distribution chart, BioCardia ranks #582 out of 1383 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioCardia has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's 6-1 Month Momentum % compare to SNTI and COCP?
According to the Biotechnology industry distribution chart, BioCardia ranks #582 out of 1383 companies for 6-1 Month Momentum %. This puts BioCardia in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on BioCardia and its competitors. BioCardia's current 6-1 Month Momentum % is -3.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (BCDA) has a current 6-1 Month Momentum % of -3.23%. The current 6-1 Month Momentum % is -3.23%. BioCardia's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For BioCardia (BCDA), the current 6-1 Month Momentum % is -3.23% as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
25GF Score
Get the complete analysis for BCDA
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCDA has been successfully added to your 
